

Study or Subgroup	Placebo/MTX		JAKI+MTX		Weight	Risk Ratio	
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI
8.1.1 Tofacitinib 5mg + MTX							
Burmester 2013	0	33	0	83		Not estimable	
Van der Hejide 2019	0	60	15	637	27.5%	0.34 [0.02, 5.57]	
Vollenhaven 2012	0	32	2	239	23.8%	1.45 [0.07, 29.64]	
Subtotal (95% CI)		125		959	51.3%	0.66 [0.09, 5.18]	
Total events	0		17				
Heterogeneity: Tau ² = 0.00; Chi ² = 0.52, df = 1 (P = 0.47); I ² = 0%							
Test for overall effect: Z = 0.39 (P = 0.70)							
8.1.2 Tofacitinib 10mg + MTX							
Burmester 2013	0	33	0	84		Not estimable	
Van der Hejide 2019	0	60	12	649	27.3%	0.43 [0.03, 7.11]	
Vollenhaven 2012	0	32	1	233	21.4%	2.36 [0.10, 56.83]	
Subtotal (95% CI)		125		966	48.7%	0.90 [0.11, 7.44]	
Total events	0		13				
Heterogeneity: Tau ² = 0.00; Chi ² = 0.67, df = 1 (P = 0.41); I ² = 0%							
Test for overall effect: Z = 0.09 (P = 0.93)							
Total (95% CI)		250		1925	100.0%	0.77 [0.18, 3.36]	
Total events	0		30				
Heterogeneity: Tau ² = 0.00; Chi ² = 1.24, df = 3 (P = 0.74); I ² = 0%							
Test for overall effect: Z = 0.34 (P = 0.73)							
Test for subgroup differences: Chi ² = 0.04, df = 1 (P = 0.84), I ² = 0%							

